Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
– Less than 1 in 10 were on any non-statin lipid lowering therapy –
– Findings were shared at the National Lipid Association Scientific Sessions –
ANN ARBOR, Mich., June 03, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) announced findings from a real-world analysis of more than 400,000 patients at high-risk for atherosclerotic cardiovascular disease (ASCVD). The findings were presented at the National Lipid Association Scientific Sessions in Scottsdale, Arizona.
“While professional guidelines are clear on defining appropriate lipid-lowering therapies for individuals at high-risk for ASCVD based on LDL-cholesterol, this analysis demonstrates major shortfalls in the real-world application of those guidelines,” said JoAnne Foody, MD, FACC, FAHA, chief medical officer of Esperion. “While LDL-cholesterol as a cardiovascular risk factor...
